ALNY vs SRBK · P/E 76, rev $1.29B vs P/E 33, rev $46.3M
Alnylam Pharmaceuticals Inc (ALNY) versus SR Bancorp, Inc. Common stock (SRBK) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
SR Bancorp, Inc. Common stock (SRBK) is a banks - regional company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported SRBK revenue for 2025-06-30 was $46.3M. Net income was $5.1M. Revenue was up 13.3% from 2024-06-30 to 2025-06-30. SRBK currently screens at market cap $140.4M and trailing P/E 32.6.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. SRBK currently screens at market cap $140.4M and trailing P/E 32.6.
Not investment advice. Open the ALNY and SRBK stock pages for the full models.
Not investment advice.